Nucala Granted Priority Review For Treatment of Hypereosinophilic Syndrome
According to a drug filing and press release from Pharmaceutical Business Review, the FDA granted a priority review to GlaxoSmithKline for their humanized monoclonal antibody therapy, Nucala (mepolizumab). Currently,…